# Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

> **NCT01256086** · PHASE2 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 44 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Formatris 24µg
- **DRUG:** Formatris 12µg
- **DRUG:** Foradil P 24µg
- **DRUG:** Foradil P 12µg

## Key facts

- **NCT ID:** NCT01256086
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256086, "Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01256086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*